Allinaire Therapeutics

Allinaire Therapeutics, LLC is a biotechnology company based in Cleveland, Ohio, established in 2015. The company focuses on developing innovative therapeutics for chronic obstructive pulmonary disease (COPD) and other pulmonary diseases, including pulmonary arterial hypertension (PAH). Allinaire's research is grounded in the discovery of a novel therapeutic target identified by its scientific founders, Irina Petrache, MD, and Matthias Clauss, Ph.D., which plays a critical role in the development and progression of lung disease. By targeting this mechanism, Allinaire Therapeutics aims to create treatment options that could significantly enhance clinical outcomes for patients suffering from various cardiopulmonary conditions.